Intervertebral disc degeneration is a common condition that may lead to low back pain and radiculopathy. Understanding the pathophysiology and cellular and molecular events of degenerative disc disease has resulted in the proposal of a gene therapy approach to halt and reverse disc degeneration. We explored the feasibility of reversing intervertebral disc degeneration using human vascular endothelial growth factor 165 (hVEGF 165 ) and transforming growth factor-β1 (TGF-β1) gene therapy. hVEGF 165 complementary DNA was obtained from pcDNA3(+)-hVEGF 165 and cloned into adeno-associated virus (AAV)-pSNAV plasmids to construct the recombinant plasmid, AAV-pSNAV-hVEGF 165 . After identification through restriction enzyme digestion and DNA sequencing, the AAV- 
ABSTRACT.
Intervertebral disc degeneration is a common condition that may lead to low back pain and radiculopathy. Understanding the pathophysiology and cellular and molecular events of degenerative disc disease has resulted in the proposal of a gene therapy approach to halt and reverse disc degeneration. We explored the feasibility of reversing intervertebral disc degeneration using human vascular endothelial growth factor 165 (hVEGF 165 ) and transforming growth factor-β1 (TGF-β1) gene therapy. hVEGF 165 complementary DNA was obtained from pcDNA3(+)-hVEGF 165 and cloned into adeno-associated virus (AAV)-pSNAV plasmids to construct the recombinant plasmid, AAV-pSNAV-hVEGF 165 . After identification through restriction enzyme digestion and DNA sequencing, the AAV-pSNAV-hVEGF 165 was transfected into HEK293 cells and vascular endothelial cells. Protein expression of hVEGF 165 was detected using a fluorescent immunohistochemical assay, and the effect of hVEGF 165 on vascular endothelial cell proliferation was determined with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Packaged AAV-hVEGF 165 and AAV-TGF-β1 were co-transfected into the annulus fibrosus cells of degenerative intervertebral discs. hVEGF 165 and TGF-β1 expression by annulus fibrosus cells and the effect of the co-transfection on the level of collagen type I protein expression by annulus fibrosus cells were detected with Western blot. The results of restriction enzyme digestion and DNA sequencing confirmed that AAV-pSNAV-hVEGF 165 plasmids were constructed. The fluorescent immunohistochemical results confirmed hVEGF 165 protein expression. The MTT results showed that the hVEGF 165 protein promoted vascular endothelial cell proliferation. Biologically active AAV-hVEGF 165 and AAV-TGF-β1 were successfully constructed. Western blot confirmed hVEGF 165 and TGF-β1 expression in annulus fibrosus cells and demonstrated that the level of collagen type I protein expression was significantly higher in annulus fibrosus cells co-transfected with both AAV-hVEGF 165 and AAV-TGF-β1 compared with that in cells transfected with AAV-hVEGF 165 or AAV-TGF-β1 alone. hVEGF 165 has a synergistic effect with TGF-β1 that promotes the expression of collagen type I protein in annulus fibrosus cells from degenerative intervertebral discs.
INTRODUCTION
Intervertebral disc degeneration is a major cause of back pain (Rubin, 2007) . In Western countries, intervertebral disc degeneration-related low back pain affects between 60 and 80% of the population at some point during life, making it one of the most important public health issues today (Urban and Winlove, 2007; Pellise et al., 2009 ). Disk degeneration is characterized by progressive loss of proteoglycans, which causes subsequent disk dehydration, disappearance of the nucleus pulposus, and defects, or collapse, of the annulus fibrosus, leading to degenerative disc diseases that include disc herniation, radiculopathy, myelopathy, spinal stenosis, instability, and low back pain (Zhao et al., 2006; Richardson et al., 2007) .
Current methods for treating degenerative disc diseases include conservative methods and surgical therapies. However, these approaches address only the clinical symptoms of intervertebral disc degeneration and do not target pathophysiological pathways involved in the degenerative process. Biological therapy, a newly developed treatment approach, can regulate disease progression at the cellular and molecular levels and may also restore disc function.
Several growth factors have been used to stimulate cell proliferation and matrix synthesis within degenerated discs. These growth factors include transforming growth factor-beta1 (TGF-β1) (Thompson et al., 1991) , bone morphogenetic protein-2 (Li et al., 2003) , osteogenic protein-1 (Takegami et al., 1999; Matsumoto et al., 2002) , growth and differentiation factor-5 (Walsh et al., 2004; Chujo et al., 2006) , insulin-like growth factor-1, epidermal growth factor, and fibroblast growth factor (Thompson et al., 1991) . In vitro studies have demonstrated that growth factors can upregulate extracellular matrix synthesis by intervertebral disc cells. However, the half-lives of these growth factors are short, and their effects do not last for significant periods of time (Franceschi et al., 2000) .
Gene therapy is an exciting technology that overcomes the limited therapeutic duration of growth factors through continuous production of these therapeutic factors (Wang et al., 1999) . Wehling et al. (1997) were the first to explore the option of gene transfer to the intervertebral disc. They used retrovirus-mediated gene transfer to successfully insert the betagalactosidase gene into in vitro cultured chondrocytes from the bovine cartilage end-plate. Nishida et al. (1999) have reported success in delivering the TGF-β1 gene into rabbit nucleus pulposus cells with a 30-fold increase in active TGF-β1 production and a 100% increase in proteoglycan production in the treated discs. However, using adeno-associated virus (AAV)-mediated dual gene expression as a therapeutic strategy has seldom been reported.
In this study, we used the angiogenesis of vascular endothelial growth factor (VEGF) for improving the nutritional diffusion and matrix synthesis-promoting effects of TGF-β1. Annulus fibrosus cells of degenerative intervertebral discs were used as target cells. AAV was selected as the vector for gene transfer, and VEGF 165 and TGF-β1 were co-transfected into annulus fibrosus cells from degenerative rabbit intervertebral discs. The synthesis of collagen type I was assessed. Our study provides a theoretical basis for in vivo experiments and the reversal of early degenerative intervertebral disc therapy using multiple gene expression.
MATERIAL AND METHODS

Plasmids, bacterial strains, viruses, and cells
The packaging plasmid AAV-pSNAV was purchased from Zhengyuan Vector Gene Technology Co., Ltd. (Beijing, China). pcDNA3(+)-VEGF 165 eukaryotic expression plasmids were a gift from Professor Yoshi Yonemitsu (Kyushu University, Japan). AAV-hVEGF 165 , AAV-TGF-β1, and AAV-enhanced green fluorescent protein (EGFP) were packaged by the Zhengyuan Vector Gene Technology Co., Ltd.. Escherichia coli DH5α, human embryonic kidney HEK293 cells, vascular endothelial cells, and rabbit annulus fibrosus cells were available in our laboratory.
Construction and identification of AAV-pSNAV-VEGF 165
The PCR primers were designed based on the hVEGF 165 complementary DNA sequence of pcDNA3(+)-hVEGF 165 . The forward primer contained the EcoRI restriction enzyme cutting site and the reverse primer contained the SalI restriction enzyme cutting site. The sequences of primers were the following: forward primer (A): 5ꞌ-ATC GGA ATT CAT GAA CTT TCG CTG-3ꞌ and reverse primer (B): 5ꞌ-ATC TGT CGA CTC ACC GCC TCG GCT T-3ꞌ. PCR was performed using pcDNA3(+)-hVEGF 165 as the template. Amplified products underwent gel electrophoresis and a 596-bp band was considered positive. PCR products were digested using both EcoRI and SalI enzymes, and hVEGF 165 fragments were collected accord-ing to manufacturer instructions included with the DNA extraction and purification kits. After identification, pSNAV was digested with both EcoRI and SalI enzymes and inserted into the collected hVEGF 165 fragments with T4 DNA ligase to obtain pSNAV-hVEGF 165 . The pSNAVhVEGF 165 was then transformed into DH5α competent E. coli. Positive clones were identified on flat-plate ALB culture medium. pSNAV-hVEGF 165 was extracted via alkaline lysis and identified through digestion and sequencing ( Figure 1 ). 
Transfection
A 12-well plate was inoculated with HEK293 cells and incubated at 37°C in a humidified 5% CO 2 atmosphere for 18-24 h. When cell confluency reached 50-60%, pSNAVhVEGF 165 was transfected into the HEK293 cells with Lipofectamine TM 2000 according to manufacturer instructions. After a 48-h incubation, the cellular supernatant was stored, and the remaining cells were used to detect the presence of hVEGF 165 protein via fluorescent immunohistochemistry. The cells were incubated with mouse anti-human VEGF monoclonal antibody (1:200) at 4°C overnight, and then immunoglobulin G-tetramethylrhodamine-5-(and 6)-isothiocyanate was added to react for 30-45 min at room temperature. The cells were washed with Tris-buffered saline buffer in darkness and then observed under a fluorescent microscope.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
A 96-well plate was inoculated with vascular endothelial cells and incubated at 37°C in a 5% CO 2 humidified atmosphere for 24 h. When cell confluency reached 60-70%, we added 0, 10, 20, 30, 40, 50, 60, 70, 80, 90 , or 100 μL Lipofectamine TM 2000. After a 24-h incubation, 20 μL MTT was added and incubated for 4 h, followed by the addition of 150 μL dimethyl sulfoxide per well. The optical density (OD) of each well at 570 nm was determined using a plate reader. The cell viability curve was derived, and hVEGF 165 protein activity was determined.
Transfection of rAAV-hVEGF 165 and Western blot
After identification, pSNAV-hVEGF 165 was used by the Vector Gene Technology Co. to construct AAV-hVEGF 165 . A 6-well plate was inoculated with fourth-passage cultured rabbit annulus fibrosus cells and incubated at 37°C for 16-18 h. When cell confluency reached 60%, cells in each well were counted and rAAV-hVEGF 165 was added according to a multiplicity of infection of 1 x 10 5 . Concurrently, AAV-EGFP was added to a well at the same multiplicity of infection to observe the transfection efficiency of AVV. After transfection, cells were incubated for an additional 72 h; Western blot was then performed to detect hVEGF 165 expression in annulus fibrosus cells.
Transfection of AAV-TGF-β1 and Western blot
The procedures for AAV-TGF-β1 transfection were the same as those for rAAVhVEGF 165 , and the identification of TGF-β1 expression in annulus fibrosus cells was the same as that for hVEGF 165 .
Co-transfection of rAAV-hVEGF 165 and AAV-TGF-β1 and Western blot
The co-transfection of rAAV-hVEGF 165 and AAV-TGF-β1 was performed as previously described. The level of expression of collagen type I protein in rabbit annulus fibrosus cells was determined by Western blot.
RESULTS
Construction and identification of pSNAV-VEGF 165
The PCR blank control showed no band (lane 1, Figure 2 ). pSNAV-VEGF 165 digested with endonuclease EcoRI showed one band after electrophoresis, confirming that the pSNAV plasmid was successfully obtained (lane 2, see Figure 2 ). PCR products were digested with both EcoRI and SalI enzymes to obtain a 581-bp hVEGF 165 fragment (lane 3, see Figure 2 ). PCR products of 596 bp containing the hVEGF 165 gene proved the successful amplification of hVEGF 165 (lane 4, see Figure 2 ). After digestion with both EcoRI and SalI enzymes, pSNAV was inserted into the 581-bp hVEGF 165 fragments with T4 DNA ligase to obtain pSNAVhVEGF 165 , which was then transformed into DH5α competent E. coli. The DH5α competent E. coli was plated on ALB culture medium at 37°C overnight, and 10 bacterial colonies were selected for amplification. pSNAV-VEGF plasmids were then extracted and identified. The results showed that two of the 10 colonies contained the pSNAV-VEGF 165 , which was digested with SmaI enzyme to obtain 812-, 839-, 1113-, and 4810-bp fragments. Only three bands appeared on the electrophoresis gel because the phase difference between the 812-and 839-bp bands was too small to be distinguishable (lane 1, Figure 3) . pSNAV was digested with endonuclease SmaI, and 839-, 1113-, and 4810-bp segments appeared (lane 2, Figure  3) . These results confirmed successful construction of pSNAV-VEGF 165 . Further sequencing results were consistent with a published VEGF 165 sequence, demonstrating the successful production of a recombinant plasmid.
Transfection of pSNAV-VEGF 165 and fluorescence immunohistochemistry
Twenty-four hours after pSNAV-VEGF 165 transfection into HEK293 cells with Lipofectamine TM 2000, a few dead cells were present; 48 h later, cell growth was robust and cell confluency reached 95% ( Figure 4A) . The supernatant was then collected, and the remaining cells were used to determine the protein expression of pSNAV-hVEGF 165 . The number of HEK293 cells in the control group was greater than that in the experimental group ( Figure  4B ). Using a fluorescent microscope, we observed VEGF 165 protein-positive fluorescence in the transfected cells ( Figure 5A ), whereas no fluorescence occurred in non-transfected control cells ( Figure 5B ). These results demonstrated that pSNAV-hVEGF 165 can express hVEGF 165 .
Effect of transfection of vascular endothelial cells with pSNAV-hVEGF 165 on cell viability
The supernatant was added to vascular endothelial cells at 60-70% fusion and incubated for 24 h. After the addition of MTT, the cells appeared blue. With the addition of supernatant, the color became more marked. Dimethyl sulfoxide was added to dissolve the MTT, and OD values at 570 nm were determined to produce a cell viability curve. The results indicated that VEGF 165 promoted cell proliferation and viability (Figure 6 ). 
Transfection of rAAV-hVEGF 165 and hVEGF 165 expression
Cell confluency reached 60% 16-18 h after rabbit annulus fibrosus cells were inoculated into a 6-well plate. At this time, rAAV-hVEGF 165 and rAAV-EGFP were transfected into the rabbit annulus fibrosus cells. Seventy-two hours later, cell fusion reached more than 80%. Fluorescent microscopy showed a high level of fluorescence excitation in rAAV-EGFP-transfected cells (Figure 7) , demonstrating that AAV effectively transfected degenerative annulus fibrosus cells with an efficiency of 40%. Western blot confirmed the expression of hVEGF 165 protein with a relative molecular weight of 45 × 10 3 in the cells (Figure 8 ). 
Transfection of AAV-TGF-β1 and TGF-β1 expression
Cell confluency reached 60% 18 h after rabbit degenerative annulus fibrosus cells were inoculated into a 6-well plate. At that time, rAAV-TGF-β1 was transfected into the cells, and 72 h later, cell confluency was more than 80%. Western blot confirmed the expression of TGF-β1 protein with a relative molecular weight of 25 x 10 3 in the degenerative annulus fibrosus cells (Figure 9 ).
Co-transfection of rAAV-hVEGF 165 and AAV-TGF-β1 and collagen type I protein expression
The cell growth status before and after transfection was the same as that previously described. The level of expression of collagen type I protein per well was determined using Western blot. The relative molecular weight of collagen type I was 300 x 10 3 . The expression of collagen type I protein was highest in cells co-transfected with AAV-hVEGF 165 and AAV-TGF-β1, second highest in cells transfected only with AAV-TGF-β1, and lowest in cells transfected with AAV-hVEGF 165 alone or in control cells. These results indicated that TGF-β1 promoted the expression of collagen type I protein in rabbit degenerative annulus fibrosus cells. hVEGF 165 alone does not directly promote the expression of collagen type I protein but has a synergetic effect with TGF-β1 in promoting the expression of this protein by these cells (Figure 10 ). 
DISCUSSION
The intervertebral disc comprises the cartilage end-plate, nucleus pulposus, and annulus fibrosus. With increasing age and the influence of various factors, such as smoking and drinking habits (Podichetty, 2007; Hangai et al., 2008) , degenerative changes gradually occur in intervertebral discs. The pathological process of degenerating intervertebral discs involves micro-damage that occurs in the annulus fibrosus and subsequent dehydration of the nucleus pulposus. Permeability of the cartilage end-plate decreases, and the number of intervertebral disc cells is reduced, leading to functional degeneration (Riches and McNally, 2005; Vernon-Roberts et al., 2008; Guehring et al., 2009) . Biochemical studies have indicated that in degenerative intervertebral discs, the level of collagen type II is reduced, and levels of collagen types I and III increase, whereas proteoglycan content (especially aggrecan) decreases with the proportion of non-aggrecan increase, and levels of chondroitin sulfate decrease and keratan sulfate increases (Fujita et al., 1993) . One factor in intervertebral disc degeneration is stress injury of the annulus fibrosus leading to micro-disruption and herniation of the nucleus pulposus. Although spontaneous repair of annulus fibrosus disruption is rare, gene therapy may be useful in effecting this repair. Gene therapy uses transfected target genes to activate degenerating intervertebral disc cells to promote the synthesis of type I and II collagen and proteoglycans and reduce their degradation, which can delay or reverse early degenerative changes and promote regeneration (Shimer et al., 2004) .
Gene therapy for degenerative intervertebral discs has been studied for less than 10 years. In 1997, Wehling et al. first proposed that transgenes could reverse intervertebral disc degeneration, and they transfected target genes into chondrocytes from bovine vertebral cartilage end-plates in vitro. In 1999, Nishida et al. transfected human TGF-β1 cDNA into nucleus pulposus cells of rabbit intervertebral discs, demonstrating an increased synthesis of proteoglycans. Wallach et al. (2003) have successfully transfected inhibitors of metalloproteinase-1 into human degenerative intervertebral disc cells, which revealed increased synthesis of proteoglycans in the nucleus pulposus. Chen and Yang (2001) have transfected TGF-β1 into rabbit degenerative nucleus pulposus cells, showing that TGF-β1 expression persists for 12 weeks and collagen and proteoglycan contents in the nucleus pulposus increased. Previous studies on gene therapy for degenerative intervertebral discs have mainly involved human TGF-β1 transfected into nucleus pulposus cells with adenovirus as the vector. In our study, AAV served as the vector, and our results indicated that it was superior to adenovirus. AAV has the following advantages: i) slight immune reaction and high safety; ii) achievement of "latent" infection status without helper viruses; iii) site-directed integration, avoiding the potential risk of host cell mutations caused by random integration; iv) extensive host range, including mitotic cells and quiescent cells; and v) stable and long-term expression of exogenous genes carried. Our results demonstrate that AAV has a higher transfection efficiency (about 40%) for annulus fibrosus cells from degenerative intervertebral discs, and that the transfected genes, VEGF 165 and TGF-β1, were expressed and played a biological role in reversing degeneration; these results confirm that AAV is a better viral vector for gene therapy.
In this study, hVEGF 165 and TGF-β1 were co-transfected into degenerative annulus fibrosus cells. hVEGF 165 , a highly specific vascular endothelium mitogen, can increase vascular permeability and promote angiogenesis and has synergetic effects with cytokines such as TGF-β1 and bone morphogenetic protein. Our results indicated that the level of collagen type I in hVEGF 165 -transfected annulus fibrosus cells was similar to that of control cells, demonstrating that hVEGF 165 specifically affects only vascular endothelial cells and has no direct effect on other cells.
TGF-β1, a cytokine with extensive biological activity, is the most important cytokine in gene therapy for degenerative intervertebral discs because it positively regulates the biological functions of nucleus pulposus and annulus fibrosus cells. Many studies have confirmed that TGF-β1 promotes the synthesis of proteoglycans and collagen type II by nucleus pulposus cells. Chen et al. (1999) have found that TGF-β1 enhances the expression of collagen type I in a dosedependent manner, reflecting the close association of TGF-β1 with fibration in degenerative discs. Our results also confirmed that the level of expression of collagen type I protein in TGF-β1-transfected annulus fibrosus cells was significantly increased compared with that in hVEGF 165 -transfected and control annulus fibrosus cells, suggesting that TGF-β1 can repair the disrupted annulus fibrosus. In this study, the level of collagen type I protein expression was significantly higher in cells co-transfected with both hVEGF 165 and TGF-β1 than in cells transfected with TGF-β1 alone, indicating the biological effects of hVEGF 165 combined with TGF-β1 are greater than those of TGF-β1 alone. Our study provides a theoretical basis for in vivo experiments and the reversal of early degeneration of the intervertebral disc using gene therapy.
